This post was originally published on this site Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men with metastatic castration-resistant prostate cancer (mCRPC), according to early results of a Phase 2 clinical trial. The study (NCT03414034) is testing whether a once-daily dose of…
This post was originally published on this site Researchers have discovered a “don’t eat me” signal that is deployed by ovarian and breast cancer cells to evade a person’s immune system. Similar to other anti-cancer therapies in use or under testing, blocking this signal raises hope for a new class of immunotherapies to combat these…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to CT053, one of CARsgen Therapeutics’ lead CAR T-cell therapies, for the treatment of patients with multiple myeloma. Chimeric antigen receptor T-cell therapy, more commonly known as CAR T-cell therapy, is a type of…
This post was originally published on this site Cellectar Biosciences announced that a second and higher dose of its investigational radiotherapeutic compound, CLR 131, was cleared for use in its ongoing CLOVER-2 study in children with advanced solid cancers, lymphomas, and brain tumors. The independent committee overseeing the trial recommended moving to a higher dose…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has drafted a series of recommendations urging the inclusion of men in breast cancer clinical trials, aiming to broaden treatment options for these patients. Men are rarely included in clinical trials assessing the effectiveness of medications to treat breast cancer…
This post was originally published on this site The rising cost of cancer care in the United States is increasingly being passed on to patients, some of whom defer or skip treatments because they can’t afford them, says the Leukemia & Lymphoma Society (LLS), which is seeking more help to address the issue. The society’s…
This post was originally published on this site A combination of tremelimumab plus Imfinzi (durvalumab) is no better than standard chemotherapy at extending the survival of people with metastatic non-small cell lung cancer (NSCLC) with a high tumor mutational burden, findings from a Phase 3 trial show. The open-label NEPTUNE trial (NCT02542293) was examining the…
This post was originally published on this site Rare diseases deeply affect not only the children who experience them, but also their healthy brothers and sisters, as their parents can attest. Two entries in November’s “Disorder: The Rare Disease Film Festival” will focus on what siblings go through, according to the San Francisco festival’s…
This post was originally published on this site A research team at the David Geffen School of Medicine at UCLA received a $1.8 million, five-year grant from the National Institutes of Health (NIH) to develop new therapeutic and preventive strategies for ovarian cancer based on the tumor suppressor p53. The team, led by Alice Soragni,…
This post was originally published on this site The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma. The therapy, collectively known as the EPd combo, is intended for patients who received at least two prior therapies, including…
